JPS5832823A - 脱癌剤 - Google Patents
脱癌剤Info
- Publication number
- JPS5832823A JPS5832823A JP12942681A JP12942681A JPS5832823A JP S5832823 A JPS5832823 A JP S5832823A JP 12942681 A JP12942681 A JP 12942681A JP 12942681 A JP12942681 A JP 12942681A JP S5832823 A JPS5832823 A JP S5832823A
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- hydroxyvitamin
- eliminating agent
- cancer
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 8
- 201000011510 cancer Diseases 0.000 title claims abstract description 8
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 11
- 239000011710 vitamin D Substances 0.000 claims abstract description 10
- 229940046008 vitamin d Drugs 0.000 claims abstract description 10
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 8
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 7
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 7
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 abstract description 5
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 abstract description 4
- JWUBBDSIWDLEOM-DCHLRESJSA-N 25-Hydroxyvitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C/C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DCHLRESJSA-N 0.000 abstract description 4
- JWUBBDSIWDLEOM-NQZHSCJISA-N 25-hydroxy-3 epi cholecalciferol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@H](O)CCC1=C JWUBBDSIWDLEOM-NQZHSCJISA-N 0.000 abstract description 4
- 238000007796 conventional method Methods 0.000 abstract description 3
- 230000004069 differentiation Effects 0.000 abstract description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract description 2
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 abstract description 2
- 229960002061 ergocalciferol Drugs 0.000 abstract description 2
- 239000012442 inert solvent Substances 0.000 abstract description 2
- 239000011630 iodine Substances 0.000 abstract description 2
- 229910052740 iodine Inorganic materials 0.000 abstract description 2
- 208000025113 myeloid leukemia Diseases 0.000 abstract description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 abstract description 2
- 235000001892 vitamin D2 Nutrition 0.000 abstract description 2
- 239000011653 vitamin D2 Substances 0.000 abstract description 2
- XQFJZHAVTPYDIQ-LETJEVNCSA-N (1s)-3-[(e)-2-[(1r,3ar,7ar)-1-[(e,2r,5r)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-1,2,3,3a,6,7-hexahydroinden-4-yl]ethenyl]-4-methylcyclohex-3-en-1-ol Chemical compound C=1([C@@H]2CC[C@@H]([C@]2(CCC=1)C)[C@H](C)/C=C/[C@H](C)C(C)C)\C=C\C1=C(C)CC[C@H](O)C1 XQFJZHAVTPYDIQ-LETJEVNCSA-N 0.000 abstract 2
- BUNBVCKYYMRTNS-UHFFFAOYSA-N tachysterol Natural products C=1CCC2(C)C(C(C)CCC(C)C(C)C)CCC2C=1C=CC1=C(C)CCC(O)C1 BUNBVCKYYMRTNS-UHFFFAOYSA-N 0.000 abstract 2
- 239000000470 constituent Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 235000005282 vitamin D3 Nutrition 0.000 abstract 1
- 239000011647 vitamin D3 Substances 0.000 abstract 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 abstract 1
- 229940021056 vitamin d3 Drugs 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 description 9
- 239000011782 vitamin Substances 0.000 description 9
- 229940088594 vitamin Drugs 0.000 description 9
- 235000013343 vitamin Nutrition 0.000 description 9
- 150000003722 vitamin derivatives Chemical class 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 238000012937 correction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000003913 calcium metabolism Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- FCCDDURTIIUXBY-UHFFFAOYSA-N lipoamide Chemical compound NC(=O)CCCCC1CCSS1 FCCDDURTIIUXBY-UHFFFAOYSA-N 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12942681A JPS5832823A (ja) | 1981-08-20 | 1981-08-20 | 脱癌剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12942681A JPS5832823A (ja) | 1981-08-20 | 1981-08-20 | 脱癌剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5832823A true JPS5832823A (ja) | 1983-02-25 |
| JPH0459298B2 JPH0459298B2 (enrdf_load_stackoverflow) | 1992-09-21 |
Family
ID=15009196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP12942681A Granted JPS5832823A (ja) | 1981-08-20 | 1981-08-20 | 脱癌剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5832823A (enrdf_load_stackoverflow) |
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58206522A (ja) * | 1982-05-26 | 1983-12-01 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| JPS58206524A (ja) * | 1982-05-26 | 1983-12-01 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| JPS58206525A (ja) * | 1982-05-26 | 1983-12-01 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| JPS58206523A (ja) * | 1982-05-26 | 1983-12-01 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| JPS58206526A (ja) * | 1982-05-26 | 1983-12-01 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| JPS58206521A (ja) * | 1982-05-26 | 1983-12-01 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| JPS58208225A (ja) * | 1982-05-28 | 1983-12-03 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| JPS58208229A (ja) * | 1982-05-28 | 1983-12-03 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| JPS58210020A (ja) * | 1982-05-31 | 1983-12-07 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| JPS58210018A (ja) * | 1982-05-31 | 1983-12-07 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| JPS58210014A (ja) * | 1982-05-31 | 1983-12-07 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| JPS58210015A (ja) * | 1982-05-31 | 1983-12-07 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| JP2009525985A (ja) * | 2006-02-03 | 2009-07-16 | プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー | ２５−ヒドロキシビタミンｄ２及び２５−ヒドロキシビタミンｄ３によるビタミンｄ不足及び欠乏の治療 |
| JP2010525050A (ja) * | 2007-04-25 | 2010-07-22 | シトクロマ インコーポレイテッド | ビタミンｄ不足および欠乏症の治療方法 |
| US9861644B2 (en) | 2013-03-15 | 2018-01-09 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
| US9918940B2 (en) | 2007-04-25 | 2018-03-20 | Opko Renal, Llc | Methods for controlled release oral dosage of a vitamin D compound |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| US10302660B2 (en) | 2008-04-02 | 2019-05-28 | Opko Renal, Llc | Methods useful for vitamin D deficiency and related disorders |
| US10668089B2 (en) | 2006-06-21 | 2020-06-02 | Opko Ireland Global Holdings, Ltd. | Method of treating and preventing secondary hyperparathyroidism |
| US11173168B2 (en) | 2016-03-28 | 2021-11-16 | Eirgen Pharma Ltd. | Methods of treating vitamin D insufficiency in chronic kidney disease |
| US11672809B2 (en) | 2010-03-29 | 2023-06-13 | Eirgen Pharma Ltd. | Methods and compositions for reducing parathyroid levels |
| US11801253B2 (en) | 2007-04-25 | 2023-10-31 | Opko Renal, Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
-
1981
- 1981-08-20 JP JP12942681A patent/JPS5832823A/ja active Granted
Cited By (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58206522A (ja) * | 1982-05-26 | 1983-12-01 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| JPS58206524A (ja) * | 1982-05-26 | 1983-12-01 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| JPS58206525A (ja) * | 1982-05-26 | 1983-12-01 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| JPS58206523A (ja) * | 1982-05-26 | 1983-12-01 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| JPS58206526A (ja) * | 1982-05-26 | 1983-12-01 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| JPS58206521A (ja) * | 1982-05-26 | 1983-12-01 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| JPS58208225A (ja) * | 1982-05-28 | 1983-12-03 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| JPS58208229A (ja) * | 1982-05-28 | 1983-12-03 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| JPS58210020A (ja) * | 1982-05-31 | 1983-12-07 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| JPS58210018A (ja) * | 1982-05-31 | 1983-12-07 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| JPS58210014A (ja) * | 1982-05-31 | 1983-12-07 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| JPS58210015A (ja) * | 1982-05-31 | 1983-12-07 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| US9943530B2 (en) | 2006-02-03 | 2018-04-17 | Opko Renal, Llc | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
| JP2009525985A (ja) * | 2006-02-03 | 2009-07-16 | プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー | ２５−ヒドロキシビタミンｄ２及び２５−ヒドロキシビタミンｄ３によるビタミンｄ不足及び欠乏の治療 |
| US11911398B2 (en) | 2006-02-03 | 2024-02-27 | Opko Renal, Llc | Treating Vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
| JP2014065751A (ja) * | 2006-02-03 | 2014-04-17 | Proventiv Therapeutics Llc | ２５−ヒドロキシビタミンｄ２及び２５−ヒドロキシビタミンｄ３によるビタミンｄ不足及び欠乏の治療 |
| US8906410B2 (en) | 2006-02-03 | 2014-12-09 | Opko Health, Inc. | Oral dosage form of 25-hydroxyvitamin D |
| US11007204B2 (en) | 2006-02-03 | 2021-05-18 | Opko Renal, Llc | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
| US10213442B2 (en) | 2006-02-03 | 2019-02-26 | Opko Renal, Llc | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
| US10668089B2 (en) | 2006-06-21 | 2020-06-02 | Opko Ireland Global Holdings, Ltd. | Method of treating and preventing secondary hyperparathyroidism |
| US11154509B2 (en) | 2007-04-25 | 2021-10-26 | Eirgen Pharma Ltd. | Methods for controlled release oral dosage of a vitamin D compound |
| JP2010525050A (ja) * | 2007-04-25 | 2010-07-22 | シトクロマ インコーポレイテッド | ビタミンｄ不足および欠乏症の治療方法 |
| JP2014055184A (ja) * | 2007-04-25 | 2014-03-27 | Cytochroma Inc | ビタミンｄ不足および欠乏症の治療方法 |
| US11801253B2 (en) | 2007-04-25 | 2023-10-31 | Opko Renal, Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
| US11752158B2 (en) | 2007-04-25 | 2023-09-12 | Eirgen Pharma Ltd. | Method of treating vitamin D insufficiency and deficiency |
| US9925147B2 (en) | 2007-04-25 | 2018-03-27 | Opko Renal, Llc | Method for treating secondary hyperparathyroidism in CKD |
| US9918940B2 (en) | 2007-04-25 | 2018-03-20 | Opko Renal, Llc | Methods for controlled release oral dosage of a vitamin D compound |
| US10302660B2 (en) | 2008-04-02 | 2019-05-28 | Opko Renal, Llc | Methods useful for vitamin D deficiency and related disorders |
| US11672809B2 (en) | 2010-03-29 | 2023-06-13 | Eirgen Pharma Ltd. | Methods and compositions for reducing parathyroid levels |
| US11253528B2 (en) | 2013-03-15 | 2022-02-22 | Eirgen Pharma Ltd. | Stabilized modified release Vitamin D formulation and method of administering same |
| US9861644B2 (en) | 2013-03-15 | 2018-01-09 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
| US10357502B2 (en) | 2013-03-15 | 2019-07-23 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
| US10350224B2 (en) | 2013-03-15 | 2019-07-16 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
| US10300078B2 (en) | 2013-03-15 | 2019-05-28 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
| US11007205B2 (en) | 2014-08-07 | 2021-05-18 | Eirgen Pharma Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| US10493084B2 (en) | 2014-08-07 | 2019-12-03 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| US11738033B2 (en) | 2014-08-07 | 2023-08-29 | Eirgen Pharma Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| US11173168B2 (en) | 2016-03-28 | 2021-11-16 | Eirgen Pharma Ltd. | Methods of treating vitamin D insufficiency in chronic kidney disease |
| US12208106B2 (en) | 2016-03-28 | 2025-01-28 | Eirgen Pharma Ltd. | Methods of vitamin D treatment |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0459298B2 (enrdf_load_stackoverflow) | 1992-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS5832823A (ja) | 脱癌剤 | |
| ES2309069T3 (es) | Compuestos de 2-etil y 2-etiliden-19-nor-vitamina d. | |
| DE60219655T2 (de) | Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung | |
| KR100231809B1 (ko) | 1알파-하이드록시 비타민 d4 및 이의 중간체 및 동족체, 및 이를 포함하는 약제학적 조성물 | |
| DE68907483T2 (de) | Vitamin d analoge. | |
| DE69307929T2 (de) | Neuen vitamin d derivate | |
| DE69308852T2 (de) | Vitamin d derivate | |
| JPH03501259A (ja) | 新規なシクロペンタノ‐ビタミンｄ類似体 | |
| KR20030032015A (ko) | 1α-히드록시-2-메틸렌-19-노르-호모프레그나칼시페롤 및그의 치료적 용도 | |
| JPH02288829A (ja) | 骨の損耗の予防又は再生不調症の治療又は予防用薬剤 | |
| KR19990022320A (ko) | 암을 치료하기 위한 비타민 ｄ₄유도체의 용도 | |
| JPH11507649A (ja) | ２５位の炭素に置換基を有する新規なビタミンｄ誘導体、その製造方法、中間生成物及び薬剤の製造のためのその使用 | |
| US20190060456A1 (en) | 1-deoxy analogs of vitamin d-related compounds | |
| DE69011872T2 (de) | Neue vitamin-d-derivate. | |
| DE69714590T2 (de) | Vitamin d analoge verbindungen | |
| DE69712086T2 (de) | Vitamin d derivate | |
| Binderup | Comparison of calcipotriol with selected metabolites and analogues of vitamin D3: effects on cell growth regulation in vitro and calcium metabolism in vivo | |
| JPS61501088A (ja) | ヒドロキシビタミンｄ↓２異性体 | |
| US5801164A (en) | Methods of treating osteoporosis prophylactically or therapeutically | |
| WO1989010352A1 (en) | SIDE CHAIN UNSATURATED 1alpha-HYDROXYVITAMIN D HOMOLOGS | |
| IL97158A (en) | Homologous histories of vitamin D in the side chain, processes for their preparation and pharmaceutical preparations containing them | |
| JPH0780773B2 (ja) | 新規ビタミンｄ▲下３▼誘導体を有効成分とする医薬 | |
| JPH0364498B2 (enrdf_load_stackoverflow) | ||
| DE3590080C2 (enrdf_load_stackoverflow) | ||
| US5756488A (en) | Composition for improving calcium metabolism |